COL6A3 and lobular neoplasia: Furthermore, immunohistochemistry and qPCR experiments were consistent with those obtained from the single-cell RNA sequencing and proteomics studies.<h4>Discussion</h4>These results proved that COL6A3 is a promising biomarker and therapeutic target, advancing personalized medicine strategies for LN.